Tislelizumab combined with Anti-GD2 antibody-based chemoimmunotherapy for pediatric relapsed/refractory high-risk neuroblastoma: a two-Case Report
Frontiers in Pharmacology · 05.08.2026 · 17
DOI: 10.3389/fphar.2026.1890595 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 05.08.2026. Verfasst von Ting Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Neuroblastoma (NB) is one of the most common extracranial solid tumors in children. Patients with high-risk metastatic disease remain at substantial risk of relapse and have poor long-term outcomes. No standard salvage regimen has been established for relapsed/refractory (R/R) NB, and the role of immune checkpoint inhibitors in pediatric NB remains investigational. Here, we report two pediatric patients with R/R high-risk NB who received a tislelizumab-containing multi-agent regimen consisting of tislelizumab, an anti-GD2 monoclonal antibody, GM-CSF support, and sequential mICE/VIT chemotherapy. The anti-GD2 antibody, dinutuximab beta or naxitamab, was selected according to each patient’s insurance coverage. Both patients tolerated treatment well, and no severe immune-related adverse events were observed during the reported follow-up period. After four cycles of combination therapy, Patient 1 showed marked regression of soft-tissue lesions and clearance of bone marrow involvement. Patient 2 achieved a complete response and remained disease-free during the 5-month follow-up period after treatment completion. However, the durability of this response remains uncertain because of the limited follow-up duration. These preliminary short-term observations suggest that this multi-agent regimen may be a feasible salvage approach for selected pediatric patients with R/R high-risk NB. However, the durability of these antitumor responses cannot be confirmed given the limited surveillance period. Notably, this retrospective two-case observation cannot distinguish the independent antitumor contribution of tislelizumab alone, as multiple therapeutic components were administered simultaneously without control groups to isolate single-agent efficacy. Larger prospective studies are warranted to further evaluate the efficacy and safety of this approach.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Department of Radiology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Zitieren
APA
Zhang, T., Liao, X., Li, Y., Yang, J., Shao, J., Zhang, H., & Jiang, S. (2026). Tislelizumab combined with Anti-GD2 antibody-based chemoimmunotherapy for pediatric relapsed/refractory high-risk neuroblastoma: a two-Case Report. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1890595
Vancouver
Zhang T, Liao X, Li Y, Yang J, Shao J, Zhang H, et al. Tislelizumab combined with Anti-GD2 antibody-based chemoimmunotherapy for pediatric relapsed/refractory high-risk neuroblastoma: a two-Case Report. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1890595
BibTeX
@article{Zhang2026,
author = {Zhang, Ting and Liao, Xuelian and Li, Yanhua and Yang, Jingwei and Shao, Jingbo and Zhang, Huanhuan and Jiang, Shayi},
title = {Tislelizumab combined with Anti-GD2 antibody-based chemoimmunotherapy for pediatric relapsed/refractory high-risk neuroblastoma: a two-Case Report},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1890595}
}
EUVIMED